Actively Recruiting
Biomarker Guided Discharge of Heart Failure Patients
Led by Ottawa Heart Institute Research Corporation · Updated on 2026-05-06
750
Participants Needed
1
Research Sites
487 weeks
Total Duration
On this page
Sponsors
O
Ottawa Heart Institute Research Corporation
Lead Sponsor
G
Genome Canada
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a multi-centre, single blind, randomized study. Patients admitted to hospital with acute decompensated heart failure will be randomized to biomarker guided discharge algorithm vs usual care in a 2:1 ratio. NTproBNP and other biomarkers will be measured within 24 hours of admission. The NTproBNP results will be used to further stratify participants randomized to the biomarker guided group into lower and medium to higher risk pathways. Biomarkers will be repeated after 2-3 days and again prior to discharge. Specific care pathways will be followed for each of the lower risk and medium-higher risk groups. Biomarkers will be repeated 30 days post discharge. Participants will be followed with a phone call at 3 months and return for a follow up visit at 6 months post discharge for outcome evaluation.
CONDITIONS
Official Title
Biomarker Guided Discharge of Heart Failure Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients admitted to hospital with a primary diagnosis of acute decompensated heart failure, compatible with the modified Framingham criteria
You will not qualify if you...
- Unable to provide blood samples or participate in follow-up
- End stage organ failure including:
- Kidney: creatinine >350 µmol/L or Estimated GFR ≤15 ml/min
- Liver dysfunction: liver function test >2.5 times normal
- Lungs: pulmonary FEV1 <50% predicted
- Requires intubation
- Admission NTproBNP measurement >30,000 pg/ml
- Listed for heart transplant or admitted for transplant workup
- In cardiogenic shock
- Life expectancy less than 6 months or major co-morbidities such as new stroke, cancer, pneumonia, or other serious life threatening illness
- Conditions making discharge difficult such as recent fall or waiting for long term care bed
- Any other significant disease or disorder that may risk patient or bias trial results
- Participation in another research trial with investigational product in past 30 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7
Actively Recruiting
Research Team
E
Ermina Moga, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here